Table of Contents
A patent portfolio analysis Paris in-house teams can put in front of a comité de direction treats patents as an asset class — something with a carrying cost, a validity risk and a market value, not just a file at the patent office. Paris and the wider ÃŽle-de-France region are the engine of French R&D, home to aerospace, automotive, luxury and pharmaceutical estates built on decades of heavy investment and a generous research tax credit. The questions asked of a portfolio here are commercial before they are legal: what is it worth in a deal, where are the gaps a rival could file into, and which renewals are quietly bleeding the budget? PerspireIP answers those questions for the R&D directors and IP counsel running French portfolios.
The work is landscape, gap, strength and valuation analysis — not litigation. It is the diligence behind an acquisition, the schedule that lets a Station F founder show real IP to a Series B investor, and the renewal-fee decision that keeps a large estate from overspending year after year at INPI and the EPO.
Why patent portfolio analysis Paris teams start with the R&D tax credit
Few cities tie research spend to filing volume as tightly as Paris does. France’s Crédit d’Impôt Recherche (CIR) reimburses 30% of eligible R&D expenditure up to €100 million, and 5% beyond that ceiling — one of the most generous research incentives in Europe. Companies that claim the CIR are expected to show for it, and patents are the most tangible proof that an R&D programme produced protectable output. The result is a large, fast-growing base of French filings: French applicants filed 10,643 European patent applications in 2024, with transport, IT and medical technology the most dynamic sectors.
That link between spend and filing is exactly why a portfolio review pays off here. A generous credit encourages volume, and volume hides waste — overlapping families, patents that no longer read on a product, renewals paid out of habit. A patent portfolio analysis Paris owners rely on separates the estate that earns its keep from the estate that merely fills a CIR justification file.
- M&A and private-equity diligence — validity, ownership chain and product coverage of a target’s patents before a bid
- Venture and growth financing — an honest read of whether the IP backs the founder’s story to a Series A or B investor
- CIR and R&D alignment — mapping the estate against the research programmes that generated it
- Board and budget reviews — a periodic strength, gap and cost picture for the direction générale and the general counsel
INPI examination since the PACTE law and what it means for strength
French patents are granted by the Institut national de la propriété industrielle (INPI), and the value of a French right changed sharply with the PACTE law. Before 22 May 2020, INPI examined applications on novelty grounds only and could not refuse a patent for lack of inventive step. For applications filed from that date, INPI conducts full substantive examination, including inventive step, applying the same problem-and-solution approach used at the EPO. A French patent granted under the new regime is a materially stronger asset than one granted before it.
PACTE also created an administrative opposition procedure at INPI, available since 1 April 2020, letting a third party challenge a granted French patent without going to court. That matters for a portfolio in two directions: your own patents can now be attacked at the office, and you can use opposition to weaken a competitor’s estate cheaply. A strength review has to grade each significant French asset for its exposure to opposition and its own filing date — pre- or post-PACTE — because the two cohorts carry very different validity profiles.
INPI also offers provisional applications and utility certificates, and it runs the national renewal system. We fold all of this into the analysis: which assets are robust modern grants, which are legacy novelty-only rights that a well-drafted opposition or nullity action could unravel, and which are worth converting, keeping or letting lapse.
Where French patent disputes land: the Tribunal judiciaire de Paris
Portfolio risk is partly forum risk, and in France the forum is singular. The Tribunal judiciaire de Paris holds exclusive national jurisdiction over French patents — every infringement, nullity and ownership dispute is heard by its specialised intellectual-property chambers, with no choice of venue anywhere else in the country. Appeals go to the Cour d’appel de Paris. First-instance judgments are typically handed down within about eighteen months, and appeals within roughly twelve, giving the French system a predictable rhythm a portfolio owner can plan around.
That concentration is an advantage for portfolio grading. A single court and a single appeal court mean one coherent body of case law on claim scope, inventive step and infringement, so a French estate can be scored against consistent precedent rather than a patchwork of regional practice. It also means the same specialist judges see the leading patentees again and again.
France’s evidence-gathering tool, the saisie-contrefaçon (infringement seizure), is authorised by the President of the Paris court and can be executed anywhere on French territory — a powerful reason to know, before any dispute, exactly which of your patents are strong enough to anchor an assertion and which a defendant would attack on validity. We flag those exposed assets so the portfolio can be strengthened or pruned in advance rather than under litigation pressure.
The UPC Central Division seat in Paris as a portfolio-risk lens
Paris is not only the home of French national litigation — it is the seat of the Central Division of the Unified Patent Court (UPC). That is decisive for any portfolio holding European patents, because a standalone revocation action against a European patent can now land physically in Paris. The Paris seat hears the largest share of technical fields: IPC section B (performing operations, transporting), D (textiles, paper), E (fixed constructions), G (physics) and H (electricity), plus all supplementary protection certificates. Chemistry (C) and mechanical engineering (F) go to the Munich section, and life sciences (A) to Milan.
For a French portfolio the implication is stark. A competitor seeking to invalidate your electronics, physics, transport or fixed-construction European patents can file a central revocation in Paris that, if successful, kills the patent across every UPC member state at once. Conversely, an opt-out decision protects a valuable classical European patent from that single point of failure. Mapping which assets sit in the Paris seat’s technical scope, and which have or have not been opted out, is core portfolio intelligence.
- France is a founding UPC member and hosts both the Central Division seat and a Paris Local Division for infringement actions
- Central revocation exposure — B, D, E, G and H patents can be attacked in Paris with pan-European effect
- Opt-out mapping — which European patents are opted out of the UPC and which are exposed to central attack
- London Agreement — France requires no translation to validate a European patent, lowering the cost of a broad French footprint
Inside Paris and ÃŽle-de-France’s aerospace, automotive and luxury estates
The Paris region’s patent base is unusually concentrated in a handful of world-leading sectors, and each hides its value in a different place. Aerospace and defence anchor the estate — Airbus, Safran, Thales and Dassault file deep families in propulsion, avionics, materials and systems. Automotive is just as strong: Valeo is consistently the leading French applicant at the EPO, alongside Stellantis, Forvia and Michelin, in electrification, ADAS and lightweighting.
- Aerospace and defence — Airbus, Safran, Thales and Dassault; dense, long-lived families where a single patent can protect a component sold for decades
- Automotive and mobility — Valeo, Stellantis, Forvia and Michelin; large, fast-moving estates heavy on electrification and driver-assistance claims
- Luxury, cosmetics and materials — L’Oréal and LVMH; formulation, device and process patents where brand and IP value are tightly linked
- Pharma, energy and public research — Sanofi, TotalEnergies and Air Liquide, plus the CEA and CNRS, two of France’s most prolific EPO applicants out of the Paris-Saclay cluster
Public research is a defining feature of the region. The CEA and CNRS file among the highest volumes in France, much of it out of the Paris-Saclay science cluster, and their patents frequently move into companies through licensing and spin-outs seeded at Station F and across Île-de-France. An estate assembled from aerospace families, automotive thickets, luxury formulations and licensed-in research output cannot be read by counting patents — each block has to be graded on its own terms, which is exactly what our analysis does.
Landscape, gap and white-space analysis for French portfolios
The offensive side of portfolio work is finding what you do not yet own. A landscape maps the patents held by you and your competitors across a technology area; a gap or white-space analysis then shows where protectable, commercially useful inventions sit unclaimed — the ground your R&D directors should be filing into before a rival does. For a CIR-funded programme, that map also demonstrates to the tax authority that research spend is producing directed, defensible IP.
For Paris aerospace, automotive and connected-hardware companies, standard-essential patents and FRAND exposure are a second landscape question. If a product implements a standard — a wireless, video-codec or automotive-connectivity standard — the portfolio carries both a liability (third-party patents declared essential that read on you) and potentially an asset (your own declared-essential patents). Mapping which of your patents read on a standard, and which external SEPs read on your products, is portfolio intelligence, not litigation.
- Competitive landscape maps — who holds what across your technology space, by assignee, claim scope and filing trend
- Gap and white-space analysis — unclaimed, protectable ground to direct the next filing programme
- Strength and coverage scoring — how well the estate actually covers the products and the roadmap
- SEP and FRAND mapping — declared-essential exposure and opportunity against the standards your products touch
How PerspireIP builds a Paris portfolio analysis you can act on
Every engagement follows the same disciplined path, scaled to whether you are prepping a data room, defending a budget or planning next year’s filings. We inventory the portfolio, verify legal status and ownership at INPI and the EPO, map each asset to products and competitors, grade strength against PACTE-era examination and UPC revocation risk, and price the estate for the transaction or decision that prompted the review.
- Full inventory with legal status, term and renewal timeline for every French and European asset
- Product-to-patent coverage mapping and a claim-strength score across the estate
- Validity grading against INPI opposition and UPC central-revocation exposure, with opt-out status flagged
- Landscape, gap and white-space maps, with SEP and FRAND exposure where relevant
- Renewal-fee pruning recommendations tied to the next INPI and EPO annuity windows
- A valuation view for M&A, financing or collateral, delivered as data-room-ready exhibits
We work alongside your in-house IP team, your corporate-development group or your outside counsel as a specialist analysis partner, deliver to your deal or budget calendar, and keep every engagement confidential. Whether you need a one-time diligence study before an acquisition, an annual portfolio health check for the board, or an ongoing pruning and landscaping programme, we scale to fit. Send us the applicant name or a patent list and we will scope a patent portfolio analysis Paris project within one business day.
IP Landscape & Resources in Paris
Key intellectual-property authorities and venues relevant to Paris:
- Institut national de la propriété industrielle (INPI) — the French patent office that grants French patents, has conducted full substantive examination including inventive step since the PACTE law, and runs the administrative opposition procedure
- Unified Patent Court (UPC) — hosts its Central Division seat in Paris, which hears revocation actions for IPC sections B, D, E, G and H with effect across all UPC member states
- European Patent Office (EPO) — grants the European patents that French applicants such as Valeo, CEA and Safran file in large volumes and that anchor most Paris portfolios
- World Intellectual Property Organization (WIPO) — PATENTSCOPE — global patent-family and publication data used for landscape, gap and white-space analysis across jurisdictions
Request a Patent Portfolio Analysis in Paris
Request a Patent Portfolio Analysis in Paris
Get a landscape, gap, strength and valuation study built for a French deal, board review or filing programme — graded against INPI’s post-PACTE examination, the Tribunal judiciaire de Paris and UPC central-revocation exposure, with renewal-fee pruning tied to your next windows. Send us the applicant name or a patent list and we will scope the work within one business day.
Explore related PerspireIP services: Patent Portfolio Analysis services · IP services in France · patent invalidation · prior art litigation search · patent infringement analysis · patent market research.
Frequently Asked Questions
What is a patent portfolio analysis, and how is it different from litigation work?
A patent portfolio analysis is a commercial and strategic review of the patents a company owns or is considering acquiring — a landscape of the competitive field, a gap or white-space map of what is unclaimed, a strength and coverage score against the products, and a valuation for a deal or a board. It is diligence and strategy, not enforcement: we are not litigating a case, we are telling you what the estate is worth, where it is weak, and what to file, keep or abandon. For Paris clients that usually supports an acquisition, a financing round, or the annual renewal budget.
How does INPI examination since the PACTE law affect my French patents?
Before 22 May 2020, INPI examined French applications on novelty only and could not refuse a patent for lack of inventive step. For applications filed from that date, INPI conducts full substantive examination including inventive step, using the same problem-and-solution approach as the EPO, so modern French grants are materially stronger assets. The PACTE law also created an administrative opposition at INPI, available since 1 April 2020, letting third parties challenge a granted French patent without going to court. Our strength review grades each asset by its filing date and its exposure to that opposition.
Where would our French patents be litigated if a dispute arose?
The Tribunal judiciaire de Paris holds exclusive national jurisdiction over French patents — every infringement, nullity and ownership case is heard by its specialised IP chambers, with no venue anywhere else in France, and appeals go to the Cour d’appel de Paris. First-instance judgments typically come within about eighteen months. France’s infringement-seizure tool, the saisie-contrefaçon, is authorised by the President of the Paris court and can be executed across the whole country. We fold all of this into a portfolio’s risk map.
Why does the UPC Central Division seat in Paris matter for my portfolio?
Paris is the seat of the Unified Patent Court’s Central Division, which hears standalone revocation actions. The Paris seat covers IPC sections B (performing operations, transporting), D (textiles, paper), E (fixed constructions), G (physics) and H (electricity), plus all SPCs; chemistry and mechanical engineering go to Munich and life sciences to Milan. If your European patents fall in the Paris scope, a competitor can seek to invalidate them in a single Paris action with effect across every UPC member state — so we map which assets are exposed and whether they have been opted out.
Do we need to translate a European patent to validate it in France?
No. France is a party to the London Agreement, so no translation is required to validate a European patent in France — a granted European patent takes effect without a French translation of the full specification. That lowers the cost of holding a broad French footprint, which is one reason so many Paris portfolios pair national French filings at INPI with European patents at the EPO. We check that your European rights are correctly in force in France and, for unitary patents, whether the unitary route or classical validation better fits the estate.
Which Paris and ÃŽle-de-France sectors do you most often analyse?
Aerospace and defence lead — Airbus, Safran, Thales and Dassault build deep, long-lived families in propulsion, avionics and materials. Automotive is just as strong, with Valeo consistently the leading French EPO applicant, alongside Stellantis, Forvia and Michelin. Luxury and cosmetics estates from L’Oréal and LVMH, pharma from Sanofi, energy and materials from TotalEnergies and Air Liquide, and prolific public research from the CEA and CNRS out of Paris-Saclay round out a base that has to be read block by block rather than by patent count.
How does a portfolio review cut renewal-fee spend?
French and European patents carry escalating annual renewal fees paid to INPI and the EPO, and across a large estate — common for CIR-funded aerospace and automotive filers — that runs to a six- or seven-figure bill, much of it on patents that no longer cover a product or block a competitor. A pruning analysis scores each asset before its next annuity window against product coverage, competitive value and resale value, so you stop paying for the assets that fail all three. For most Paris portfolios the exercise pays for itself at the first major renewal decision it informs.